NCT02624596View on ClinicalTrials.gov

Understanding How Ketamine Brings About Rapid Improvement in OCD

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Ketamine

OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion

DRUG

Midazolam

OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

University of Connecticut

OTHER

lead

Stanford University

OTHER